Optimizing Treatment for Major Depressive Disorder with Previous Suicide Attempt

Immediate Action: Dose Optimization

The American College of Physicians recommends increasing the sertraline dose to at least 50mg, as the current 25mg dose is subtherapeutic and inadequate for treating major depressive disorder, with monitoring within 1-2 weeks 1
The minimum licensed dose of sertraline for MDD is 50mg daily, and therapeutic dosing typically ranges from 50-200mg/day, with an adequate antidepressant trial requiring minimum licensed dosing for at least 4 weeks 1, 2, 3
Increase to 50mg immediately and assess response within 6-8 weeks before considering this an adequate trial, with moderate-quality evidence supporting this approach 1

Intensive monitoring should begin within 1-2 weeks of any dose change, as suicide risk is greatest during the first 1-2 months of treatment, with a focus on emergence of agitation, irritability, unusual behavioral changes, and worsening suicidal ideation 1
SSRIs are associated with increased risk for suicide attempts compared to placebo, particularly early in treatment, highlighting the need for close monitoring 1

If no adequate response after 6-8 weeks at therapeutic dosing, consider switching to bupropion, venlafaxine, or another SSRI, with moderate-quality evidence showing no difference in response rates when switching between second-generation antidepressants 4, 5
Bupropion has lower rates of sexual adverse events than sertraline, which may improve adherence, and augmentation with bupropion or aripiprazole may be considered, with low-quality evidence showing augmentation with bupropion decreases depression severity more than buspirone 1, 4, 5
Recent evidence suggests aripiprazole augmentation may achieve higher remission rates, and augmenting current medication with CBT may also be effective, with moderate-quality evidence showing CBT combined with antidepressants or as monotherapy has similar efficacy to antidepressants alone 5, 6, 7

Medication adherence is critical, with poor or intermittent adherence increasing suicide attempt risk, and ensuring the patient understands the need for consistent daily dosing is essential 1
Continue treatment for 4-9 months after achieving satisfactory response for first episode, and for patients with previous suicide attempts, longer duration therapy is beneficial 1
The American Psychiatric Association recommends monitoring for additional risk factors, such as stressful life events and alcohol use, which significantly increase suicide attempt risk, and addressing these concurrent issues as part of comprehensive treatment 1